Our research group also reported that EGFR signaling promoted inflammation and cancer stem-like cell activity in IBC [6], and the EGFR pathway is a promising therapeutic target for patients with triple-negative IBC (TN-IBC) [7, 8]. The gene discussed is EGFR; the disease is inflammatory breast carcinoma.